Searched for
MANKIND PHARMA REVENUE INCREASE
Mankind Pharma among 5 F&O stocks with a sharp rise in futures open interestFive NSE F&O stocks recorded a rise of over 7% in futures open interest on October 26, with Radico Khaitan leading at 16.05%, followed by M...- Mankind Pharma Q2 profit rises 38% to Rs 716 croreMankind Pharma has announced a profit increase of 37.7% to ₹716 crore during the September quarter. Revenue from operations rose to ₹4,337....
- Stocks in news: Paytm, Tata Consumer, Dalmia Bharat, REC and DCM ShriramIndian equity markets showed recovery with a rise in NSE Nifty 50, ending a four-session losing streak. Several companies reported their Se...
- Paytm Q2 Results: Profit rockets 976% YoY to Rs 226 crore, revenue jumps 28%Paytm Q2 Results: Fintech major Paytm on Monday reported 976% year-on-year (YoY) growth in its consolidated net profit at Rs 226 crore. The...
- India’s outward FDI falls 14% to $4.34 billion in September as loans, guarantees declineOutward foreign direct investment from India reached $4.34 billion in September, which is a 14% increase from last year. However, this figu...
- Mankind Pharma shares key business developments from Q2 & H1 of FY27The company outperformed the market by 1.1 times in both chronic and acute therapies. Cardiac and anti-diabetes brands registered growth of...
- Tata Consumer Q2 Results: Net profit rises 16% YoY to Rs 470 crore, revenue up 14%Tata Consumer Products reported a 16% year-on-year profit increase to Rs 470 crore in Q2 FY27, with revenue rising 14% to Rs 5,661 crore. S...
- Coforge slips 3% even as Jefferies, Nomura, others raise targets after Q2 earnings. Why are they bullish?Coforge shares fell despite strong Q2 results and brokerages raising target prices. Net profit surged 56.5% year-on-year to Rs 588.1 crore,...
- Stocks in news: Infosys, Kotak Mahindra Bank, YES Bank, Raymond, BPCL, Coforge and Senco GoldIndian equity markets have faced a decline for four consecutive sessions, with the Nifty falling significantly. Various factors, including ...
- Indian pharma: Unethical practices, marketing rules under lens; new review body set upThe review comes against the backdrop of the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), which was introduced in 2015 as a...
- Infosys Q2 Results: Profit rises 6% YoY to Rs 7,823 crore; co lowers revenue guidanceInfosys Q2 Results: IT services major Infosys Ltd on Friday reported 6% year-on-year (YoY) growth in its consolidated net profit at Rs 7,82...
- Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruptionDr Reddy’s Laboratories has expanded its generic semaglutide portfolio with Obeda Pro and Obeda Plus after supplies of its original Obeda i...
- A Japanese giant is quietly taking a bigger shelf in India’s wardrobesUniqlo India's revenue increased by 44% to Rs 1,724 crore in the last financial year. The brand's focus on everyday essentials contrasts wi...
- Swiggy Q2 revenue jumps 36%; loss narrows to Rs 922 croreThe company’s food delivery gross order value (GOV) increased 17.7% year-on-year to Rs 10,054 crore, up 5.9% from the previous month. Swigg...
- IGI Q2 Results: Consolidated PAT surges 43% to Rs 185 croreThe International Gemological Institute recently announced an impressive 43.14 percent growth in profit after tax for the previous quarter....
- Sun Pharma to raise Rs 10,000 crore to part-finance Organon dealSun Pharmaceutical Industries plans to raise ₹10,000 crore through two tranches of rupee-denominated bonds. The funds will help refinance b...
- Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select playersIndia's pharmaceutical companies are expected to have a mixed performance in the upcoming September quarter. Companies like Sun Pharmaceuti...
- Ixigo reports 13% revenue growth in Q2; posts Rs 63 crore in net profitIxigo has reported a remarkable turnaround for the September quarter, showcasing a 13% year-on-year revenue growth, reaching Rs 321 crore. ...
- Stocks in news: RIL, Wipro, Jio Financial, Tata Communications, YES Bank, PNBFrom a technical perspective, the 23,000–23,100 zone remains an immediate resistance level for the Nifty, according to Ponmudi R, CEO of En...
- CPHI Milan: Beyond generics, how Indian pharma is rewriting its global playbookAt CPHI Milan, Indian pharma players are looking beyond traditional exports, using partnerships, licensing, CDMO, and differentiated produc...
Load More
